Dendritic cell-based glioma immunotherapy (review).
Despite advances in radiation and chemotherapy along with surgical resectioning, the prognosis of patients with malignant glioma is poor. Among the new treatments currently being investigated for malignant glioma, immunotherapy is theoretically very attractive, since it offers the potential for high tumor-specific cytotoxicity. There are increasing reports demonstrating that systemic immunotherapy using dendritic cells is capable of inducing an antiglioma response. Therefore, dendritic cell-based immunotherapy could be a new treatment modality for patients with glioma. In this review, we will discuss the implications of these findings for glioma therapy. A literature review of dendritic cell-based glioma immunotherapy was used to overview the dendritic cell in immunobiology, in the central nervous system and in tumor immunology, glioma-associated antigens, dendritic cell therapy in animal glioma model, dendritic cell therapy in clinical trials and future directions in dendritic cell therapy. Dendritic cell-based immunotherapy strategies appear promising as an approach to successfully induce an antitumor immune response and increase survival in patients with glioma. Dendritic cell therapy of glioma seems to be safe and without major side effects. Its efficacy should be further determined in randomized, controlled clinical trials. The development of methods for manipulating dendritic cells for the purpose of vaccination will enhance the clinical usefulness of these cells for biotherapy for malignant glioma.
Yamanaka
Ryuya
R
Department of Neurosurgery, Brain Research Institute, Niigata University, Asahimachi-dori 1-757, Niigata City 951-8585, Japan. ryaman@pop11.odn.ne.jp
Yajima
Naoki
N
Abe
Takashi
T
Tsuchiya
Naoto
N
Homma
Junpei
J
Narita
Miwako
M
Takahashi
Masuhiro
M
Tanaka
Ryuichi
R
D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology; D002490:Central Nervous System / Q000502:physiology; D002986:Clinical Trials as Topic; D003713:Dendritic Cells / Q000378:metabolism*; D005910:Glioma / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D051379:Mice; D008810:Mice, Inbred C57BL; D008953:Models, Anatomic; D008954:Models, Biological; D051381:Rats; D011916:Rats, Inbred F344; D016896:Treatment Outcome
D000951:Antigens, Neoplasm